# US 2010/0166835 A1 · Compositions and uses thereof for the treatment of wounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166835 A1
- Document ID: US20100166835A1
- Status: Published application
- Kind: A1
- Application number: 12/441,691
- Filed: 2007-02-06
- Published: 2010-07-01
- Earliest claimed: 2006-09-19
- Assignees: Phylogica Limited; The McComb Foundation, Inc.
- Inventors: Mark Fear; Paul Watt; Richard Hopkins; Nadia Milech
- Web page: https://patentgrep.com/patent/US20100166835A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.

## Claims

### Claim 1

A topical composition comprising (i) an amount of a peptide or peptide analog that is an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient.

### Claim at position 2

2-8. (canceled)

### Claim 9 (depends on 1)

The topical composition according to claim 1 wherein the peptide or peptide analogue comprises a protein transduction domain or an analogue thereof.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The topical composition according to claim 1 wherein the carrier or excipient is a topical carrier or excipient or other carrier or excipient for dermal application.

### Claim 12 (depends on 11)

The topical composition according to claim 11 wherein the carrier or excipient provides a buffering activity to maintain the AP-1 inhibitor at a suitable pH to thereby exert its biological activity.

### Claim at position 7

13-14. (canceled)

### Claim 15 (depends on 1)

The topical composition according to claim 1 wherein the carrier or excipient comprises a compound that enhances cellular uptake of the AP-1 signaling inhibitor and/or enhances transdermal delivery of the AP-1 signaling inhibitor.

### Claim 16 (depends on 1)

The topical composition according to claim 1 additionally comprising a growth factor to and/or an antibiotic and/or an anaesthetic.

### Claim 17 (depends on 1)

The topical composition according to claim 1 wherein the composition is a liquid or a cream or a gel or a lotion.

### Claim 18 (depends on 1)

The topical composition according to claim 1 wherein the composition is a liquid.

### Claim at position 12

19-20. (canceled)

### Claim 21 (depends on 1)

A wound dressing comprising the topical composition according to claim 1.

### Claim 22 (depends on 21)

The wound dressing according to claim 21, wherein the dressing is a fabric bandage or a plastic bandage or a gauze bandage or a gauze dressing or a trauma dressing impregnated.

### Claim 23 (depends on 21)

The wound dressing according to claim 21, wherein the dressing is a bio-degradable scaffold.

### Claim 24 (depends on 1)

A method for producing the topical composition according to claim 1 comprising mixing or otherwise combining (i) an amount of a peptide or peptide analog that is an AP-1 signaling inhibitor sufficient to reduce or prevent apoptosis and/or necrosis induced by dermal wounding and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient.

### Claim 25 (depends on 24)

The method according to claim 24 additionally comprising producing or obtaining the peptide or peptide analog.

### Claim at position 18

26-27. (canceled)

### Claim 28 (depends on 1)

A method of treating a dermal wound, the method comprising topically administering to a subject in need thereof the topical composition according to claim 1, for a time and under conditions sufficient for the peptide or peptide analog to reduce or prevent apoptosis and/or necrosis induced by dermal wounding and/or enhance proliferation of a cell, thereby treating the dermal wound.

### Claim 29 (depends on 28)

The method according to claim 28 comprising topically administering the topical composition to a region of a dermal layer surrounding a dermal wound.

### Claim 30

(canceled)

### Claim 31 (depends on 28)

The method according to claim 28 wherein the peptide is administered by topically administering a recombinant cell expressing said peptide to the subject.

### Claim 32

(canceled)

### Claim 33 (depends on 28)

The method according to claim 28 for treating an ulcer.

### Claim 34

(canceled)

### Claim 35 (depends on 28)

The method according to claim 28 for treating a burn.

### Claim at position 27

36-41. (canceled)

### Claim 42 (depends on 1)

The topical composition according to claim 1 for treating a dermal wound.

### Claim at position 29

43-45. (canceled)
